Early research has identified a new chemical that was able to stimulate nerve growth in lab-grown cells and help animals with damaged nerves regain muscle movement.
FDA analysts have flagged concerns over the risk of preterm birth for the shot, which is given to pregnant people to protect infants from RSV in their first months of life.